Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Exxon Mobil Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Exxon Mobil Corporation trades at $140.48 (market cap $575.65B). The key difference: Exxon Mobil Corporation is far larger — about 14.4× Alnylam Pharmaceuticals, Inc.'s market cap, and Exxon Mobil Corporation pays a 2.97% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | XOM | |
|---|---|---|
Market Cap | $39.89B | $575.65B |
Sector | Health | Energy |
52-Week High | $491.22 | $171.52 |
52-Week Low | $278.09 | $105.83 |
Enterprise Value | $38.15B | $614.88B |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ExxonMobil (XOM) trades at $138.83, up 1.06% with a bearish technical signal despite recent earnings beats. The company shows declining revenue ($323.9B in 2025) and profit margins (8.9% in 2025) but maintains strong cash flow from operations ($52B). Analyst consensus is mixed with 43% buy ratings and a $169.30 price target, while recent news highlights Exxon's Permian Basin advantages and warnings about potential oil price spikes to $160 per barrel.
XOM faces headwinds from declining profitability but offers value through its low breakeven Permian operations and dividend yield. The stock's upside depends on oil price stability and execution of production growth targets, while risks include volatile energy markets and ongoing margin compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
